Our results show that injected CD30 aptamer-reporters rapidly accumulate (<10 min) into CD30-positive tumor sites, but not into CD30-negative tumor sites, with the imaging signal intensity 4–8-fold higher than in control tumors and body background levels. This evidence concerns the gene TNFRSF8 and neoplasm.